1. Antibiotic prophylaxis in neutropenic children with acute leukemia: Do the presently available data really support this practice?
- Author
-
Elio Castagnola, Eliana Ruberto, and Carmelina Calitri
- Subjects
medicine.medical_specialty ,Neutropenia ,Fever ,medicine.drug_class ,Antibiotics ,Pediatrics ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,Antibiotic prophylaxis ,Child ,Acute leukemia ,business.industry ,Hematopoietic Stem Cell Transplantation ,Cancer ,Hematology ,General Medicine ,Bacterial Infections ,Antibiotic Prophylaxis ,medicine.disease ,Anti-Bacterial Agents ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,business ,Febrile neutropenia - Abstract
Antibiotics are frequently administered for prophylaxis of fever in neutropenic children with cancer. This strategy is mainly derived from adults' data, and various pediatric studies evidenced the effectiveness of antibiotics (eg, fluoroquinolones) in the prevention of febrile neutropenia. However, only two pediatric randomized, double-blind, placebo-controlled trials have been performed, with a total of 262 leukemic children enrolled, and no other one was ever powered for analyzing effectiveness over other infectious complications. In an era of increasing antibiotic resistance, the widespread use of antibiotic prophylaxis in neutropenic leukemic children needs to be strongly supported.
- Published
- 2018